

Resistance or Defiance? The FDA and the 11th Circuit Spar Over Statute on Orphan Drug Statutory Exclusivity

February 23, 2023

ATTORNEYS

Landmon, Chad

Chad Landmon

Clinical Leader

PRACTICE AREAS

FDA

Intellectual Property

Axinn partner Chad Landmon authored the *Clinical Leader* article, "Resistance or Defiance? The FDA and the 11th Circuit Spar Over Statute on Orphan Drug Statutory Exclusivity."

Click [here](#) to access the article.